Autoantibody biomarkers in prostate cancer

Laboratory Medicine

Volumn 39, Issue 3, 2008, Pages 165-171

  Wang, Xiaoju ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 62749199172     PISSN: 00075027     EISSN: None     Source Type: Journal    
DOI: 10.1309/AW0XDAV6KV4AVLRG     Document Type: Article

References (64)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
2. McDavid K, Lee J, Fulton JP, et al. Prostate cancer incidence and mortality rates and trends in the United States and Canada. Public Health Rep. 2004;119:174-186.
3. Miller DC, Hafez KS, Stewart A, et al. Prostate carcinoma presentation, diagnosis, and staging: An update form the National Cancer Data Base. Cancer. 2003;98:1169-1178.
4. Ries LA, Wingo PA, Miller DS, et al. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer. 2000;88:2398-2424.
5. Catalona WJ. Management of cancer of the prostate. N Engl J Med. 1994;331:996-1004.
6. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004;350:2239-2246.
7. Old LJ, Chen YT. New paths in human cancer serology. J Exp Med. 1998;187:1163-1167.
8. Mintz PJ, Kim J, Do KA, et al. Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol. 2003;21:57-63.
9. Nilsson BO, Carlsson L, Larsson A, et al. Autoantibodies to prostasomes as new markers for prostate cancer. Ups J Med Sci. 2001;106:43-49.
10. Stockert E, Jager E, Chen YT, et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med. 1998;187:1349-1354.
11. Brichory FM, Misek DE, Yim AM, et al. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci USA. 2001;98:9824-9829.
12. Finn OJ. Immune response as a biomarker for cancer detection and a lot more. N Engl J Med. 2005;353:1288-1290.
13. Sahin U, Tureci O, Schmitt H, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA. 1995;92:11810-11813.
14. Chen YT, Gure AO, Tsang S, et al. Identification of multiple cancer/ testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci USA. 1998;95:6919-6923.
15. Minenkova O, Pucci A, Pavoni E, et al. Identification of tumor-associated antigens by screening phage-displayed human cDNA libraries with sera from tumor patients. Int J Cancer. 003;106:534-544.
16. Zhong L, Peng X, Hidalgo GE, et al. Antibodies to HSP70 and HSP90 in serum in non-small cell lung cancer patients. Cancer Detect Prev. 2003;27:285-290.
17. Soussi T. p53 Antibodies in the sera of patients with various types of cancer: A review. Cancer Res. 2000;60:1777-1788.
18. Zhang JY, Zhu W, Imai H, Kiyosawa K, Chan EK, Tan EM. De-novo humoral immune responses to cancer-associated autoantigens during transition from chronic liver disease to hepatocellular carcinoma. Clin Exp Immunol. 2001;125:3-9.
19. Daniels T, Zhang J, Gutierrez I, et al. Antinuclear autoantibodies in prostate cancer: immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis. Prostate. 2005;62:14-26.
20. Zhou Y, Toth M, Hamman MS, et al. Serological cloning of PARIS-1: A new TBC domain-containing, immunogenic tumor antigen from a prostate cancer cell line. Biochem Biophys Res Commun. 2002;290:830-838.
21. Shi FD, Zhang JY, Liu D, et al. Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens. Prostate. 2005;63:252-258.
22. Pontes ER, Matos LC, da Silva EA, et al. Auto-antibodies in prostate cancer: humoral immune response to antigenic determinants coded by the differentially expressed transcripts FLJ23438 and VAMP3. Prostate. 2006;66:1463-1473.
23. Smith RA, Cokkinides V, Eyre HJ. American Cancer Society Guidelines for the Early Detection of Cancer, 2005. CA Cancer J Clin. 2005;55:31-44; quiz 55-36.
24. Zisman A, Zisman E, Lindner A, et al. Autoantibodies to prostate specific antigen in patients with benign prostatic hyperplasia. J Urol. 1995;154:1052-1055.
25. McNeel DG, Nguyen LD, Storer BE, et al. Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer. J Urol. 2000;164:1825-1829.
26. Chu TM, Kuriyama M, Johnson E, et al. Circulating antibody to prostate antigen in patients with prostatic cancer. Ann N Y Acad Sci. 1983;417:383-389.
27. Olayioye MA, Neve RM, Lane HA, et al. The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J. 2000;19:3159-3167.
28. Menard S, Pupa SM, Campiglio M, et al. Biologic and therapeutic role of HER2 in cancer. Oncogene. 2003;22:6570-6578.
29. Osman I, Scher HI, Drobnjak M, et al. HER2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res. 2001;7:2643-2647.
30. Morris MJ, Reuter VE, Kelly WK, et al. HER2 profiling and targeting in prostate carcinoma. Cancer. 2002;94:980-986.
31. Hernes E, Fossa SD, Berner A, et al. Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence. Br J Cancer. J2004;90:449-454.
32. Calvo BF, Levine AM, Marcos M, et al. Human epidermal receptor-2 expression in prostate cancer. Clin Cancer Res. 2003;9:1087-1097.
33. Signoretti S, Montironi R, Manola J, et al. HER2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst. 2000;92:1918-1925.
34. Shi Y, Brands FH, Chatterjee S, et al. HER2/neu expression in prostate cancer: High level of expression associated with exposure to hormone therapy and androgen independent disease. J Urol. 2001;166:1514-1519.
35. Morote J, de Torres I, Caceres C, et al. Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastasic prostate cancer. Int J Cancer. 1999;84:421-425.
36. Kalchman MA, Koide HB, McCutcheon K, et al. HIP1, a human homologue of S. cerevisiae Sla2p, interacts with membrane-associated huntingtin in the brain. Nat Genet. 1997;16:44-53.
37. Rao DS, Hyun TS, Kumar PD, et al. Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival. J Clin Invest. 2002;110:351-360.
38. Bradley SV, Oravecz-Wilson KI, Bougeard G, et al. Serum antibodies to huntingtin interacting protein-1: A new blood test for prostate cancer. Cancer Res. 2005;65:4126-4133.
39. Jamora C, Dennert G, Lee AS. Inhibition of tumor progression by suppression of stress protein GRP78/BiP induction in fibrosarcoma B/ C10ME. Proc Natl Acad Sci USA. 1996;93:7690--7694.
40. Reddy RK, Mao C, Baumeister P, et al. Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: Role of ATP binding site in suppression of caspase-7 activation. J Biol Chem. 2003;278:20915-20924.
41. Shuda M, Kondoh N, Imazeki N, et al. Activation of the ATF6, XBP1 and grp78 genes in human hepatocellular carcinoma: a possible involvement of the ER stress pathway in hepatocarcinogenesis. J Hepatol. 2003;38(5):605-614.
42. Gazit G, Lu J, Lee AS. De-regulation of GRP stress protein expression in human breast cancer cell lines. Breast Cancer Res Treat. Mar 1999;54:135-146.
43. Sreekumar A, Laxman B, Rhodes DR, et al. Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. J Natl Cancer Inst. 2004;96:834-843.
44. Xu J, Stolk JA, Zhang X, et al. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res. 2000;60:1677-1682.
45. Luo JH, Yu YP, Cieply K, et al. Gene expression analysis of prostate cancers. Mol Carcinog. 2002;33:25-35.
46. Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer. Nature. 2001;412:822-826.
47. Welsh JB, Sapinoso LM, Su AI, et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res. 2001;61:5974-5978.
48. Rhodes DR, Barrette TR, Rubin MA, et al. Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res. 2002;62:4427-4433.
49. Jiang Z, Woda BA, Rock KL, et al. P504S: A new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol. 2001;25:1397-1404.
50. Rubin MA, Zhou M, Dhanasekaran SM, et al. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA. 2002;287:1662-1670.
51. Luo J, Zha S, Gage WR, et al. Alpha-Methylacyl-CoA racemase: A new molecular marker for prostate cancer. Cancer Res. 2002;62:2220-2226.
52. Jiang Z, Wu CL, Woda BA, et al. Alpha-methylacyl-CoA racemase: A multi-institutional study of a new prostate cancer marker. Histopathology. 2004;45:218-225.
53. Kuefer R, Varambally S, Zhou M, et al. alpha-Methylacyl-CoA racemase: Expression levels of this novel cancer biomarker depend on tumor differentiation. Am J Pathol. 2002;161:841-848.
54. Krebs EG, Beavo JA. Phosphorylation-dephosphorylation of enzymes. Annu Rev Biochem. 1979;48:923-959.
55. Cho YS, Park YG, Lee YN, et al. Extracellular protein kinase A as a cancer biomarker: Its expression by tumor cells and reversal by a myristate-lacking Calpha and RIIbeta subunit overexpression. Proc Natl Acad Sci USA. 2000;97:835-840.
56. Cvijic ME, Kita T, Shih W, et al. Extracellular catalytic subunit activity of the cAMP-dependent protein kinase in prostate cancer. Clin Cancer Res. 2000;6:2309-2317.
57. Kita T, Goydos J, Reitman E, et al. Extracellular cAMP-dependent protein kinase (ECPKA) in melanoma. Cancer Lett. 2004;208:187-191.
58. Nesterova MV, Johnson N, Cheadle C, et al. Autoantibody cancer biomarker: Extracellular protein kinase A. Cancer Res. 2006;66:8971-8974.
59. Fabiani R. Functional and biochemical characteristics of human prostasomes. Minireview based on a doctoral thesis. Ups J Med Sci. 1994;99:73-111.
60. Larsson A, Ronquist G, Wulfing C, et al. Antiprostasome antibodies: possible serum markers for prostate cancer metastasizing liability. Urol Oncol. 2006;24:195-200.
61. Koziol JA, Zhang JY, Casiano CA, et al. Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res. 2003;9:5120-5126.
62. Zhang JY, Casiano CA, Peng XX, et al. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev. 2003;12:136-143.
63. Zhong L, Peng X, Hidalgo GE, et al. Identification of circulating antibodies to tumor-associated proteins for combined use as markers of non-small cell lung cancer. Proteomics. 2004;4:1216-1225.
64. Wang X, Yu J, Sreekumar A, et al. Autoantibody signatures in prostate cancer. N Engl J Med. 2005;353:1224-1235.